We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

3 hedge funds and large institutions have $23.2M invested in Decoy Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3 → 3 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

21% less capital invested

Capital invested by funds: $29.5M → $23.2M (-$6.29M)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.08M
2
Primecap Management
Primecap Management
California
+$4.08M

Top Sellers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
-$4.08M
2
Jennison Associates
Jennison Associates
New York
-$1.73M
3
Lazard Asset Management
Lazard Asset Management
New York
-$876K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$128K
5
TI
Trexquant Investment
Connecticut
-$73K

DCOY Hedge Fund Activity: Q1 2017 in Review

3 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q1 2017, worth a combined $23.2M — down 21% from $29.5M a quarter earlier.

Fund positioning in DCOY was balanced in Q1 2017: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $4.08M. The largest seller was Ameriprise, exiting entirely with an estimated $4.08M sold.

  • 3 institutional investors held Decoy Therapeutics (DCOY) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $23.2M of Decoy Therapeutics stock for Q1 2017, down 21% quarter-over-quarter.
  • 1 fund opened new Decoy Therapeutics positions in Q1 2017 and 1 closed out, a net change of 0 holders.
  • The largest Decoy Therapeutics buyer in Q1 2017 was BlackRock, an estimated $4.08M added.
  • The largest Decoy Therapeutics seller in Q1 2017 was Ameriprise, an estimated $4.08M sold.

Based on aggregated 13F filings for Q1 2017.